Development of a microparticulate prostate cancer vaccine and evaluating the effect of route of administration on its efficacy via the skin

References

• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers – liposomes and microspheres – on the phagocytosis by macrophages. J Control Release, 2002;79:29–40
   PubMed Web of Science ®Google Scholar
• Akalkotkar A, Tawde SA, Chablani L, D'Souza MJ. Oral delivery of particulate prostate cancer vaccine: In vitro and in vivo evaluation. J Drug Target, 2012;20:338–46
   PubMed Web of Science ®Google Scholar
• Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA. Advances in transcutaneous vaccine delivery: Do all ways lead to Rome? J Control Release, 2010;148:266–82
   PubMed Web of Science ®Google Scholar
• Bhowmik T, D'Souza B, Shashidharamurthy R, Oettinger C, Selvaraj P, D'Souza MJ. A novel microparticulate vaccine for melanoma cancer using transdermal delivery. J Microencapsul, 2011;28:294–300
   PubMed Web of Science ®Google Scholar
• Bumgarner GW. 2001. Evaluation of the microparticle as an adjuvant or coadjuvant in a tumor vaccine. Atlanta, GA: Mercer University
   Google Scholar
• Cavacini LA, Duval M, Eder JP, Posner MR. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. Clin Cancer Res, 2002;8:368–73
   PubMed Web of Science ®Google Scholar
• Chablani L, Tawde SA, D'Souza MJ. Spray-dried microparticles: A potential vehicle for oral delivery of vaccines. J Microencapsul, 2012;29(4):388–97
   PubMed Web of Science ®Google Scholar
• Cilurzo F, Selmin F, Gennari CG, Montanari L, Minghetti P. Application of methyl methacrylate copolymers to the development of transdermal or loco-regional drug delivery systems. Expert Opin Drug Deliv, 2014;11(7):1033–45
   PubMed Web of Science ®Google Scholar
• Cook IF. Evidence based route of administration of vaccines. Hum Vaccin, 2008;4:67–73
   PubMed Web of Science ®Google Scholar
• D’Souza B, Bhowmik T, Shashidharamurthy R, Oettinger C, Selvaraj P, D'Souza M. Oral microparticulate vaccine for melanoma using M-cell targeting. J Drug Target, 2012;20:166–73
   PubMed Web of Science ®Google Scholar
• Erni C, Suard C, Freitas S, Dreher D, Merkle HP, Walter E. Evaluation of cationic solid lipid microparticles as synthetic carriers for the targeted delivery of macromolecules to phagocytic antigen-presenting cells. Biomaterials, 2002;23:4667–76
   PubMed Web of Science ®Google Scholar
• Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm, 2005;298:315–22
   PubMed Web of Science ®Google Scholar
• Gayakwad SG, Bejugam NK, Akhavein N, Uddin NA, Oettinger CE, D'Souza MJ. Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-kappaB encapsulated albumin microspheres. J Microencapsul, 2009;26:692–700
   PubMed Web of Science ®Google Scholar
• Jensen MM, Jorgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging, 2008;8:16
   PubMedGoogle Scholar
• Kalluri H, Kolli CS, Banga AK. Characterization of microchannels created by metal microneedles: Formation and closure. AAPS J, 2011;13:473–81
   PubMed Web of Science ®Google Scholar
• Kanke M, Sniecinski I, DeLuca PP. Interaction of microspheres with blood constituents: I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. J Parent Sci Technol, 1983;37:210–17
   PubMedGoogle Scholar
• Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release, 2010;142:187–95
   PubMed Web of Science ®Google Scholar
• Kim MH, Park DH, Yang JH, Choy YB, Choy JH. Drug-inorganic-polymer nanohybrid for transdermal delivery. Int J Pharm, 2013.;444(1–2):120–7
   PubMed Web of Science ®Google Scholar
• Lai YH, D'Souza MJ. Formulation and evaluation of an oral melanoma vaccine. J Microencapsul, 2007;24:235–52
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Laurent PE. Cutaneous delivery of prophylactic and therapeutic vaccines: Historical perspective and future outlook. Expert Rev Vaccin, 2008;7:1329–39
   PubMed Web of Science ®Google Scholar
• Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev, 2001;50:143–56
   PubMed Web of Science ®Google Scholar
• Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood, 2007;109:5346–54
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: Implications for vaccine development. Cell, 2006;124:849–63
   PubMed Web of Science ®Google Scholar
• Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med, 2010;207:637–50
   PubMed Web of Science ®Google Scholar
• Song JM, Kim YC, Barlow PG, Hossain MJ, Park KM, Donis RO, Prausnitz MR, Compans RW, Kang SM. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res, 2010;88:244–7
   PubMed Web of Science ®Google Scholar
• Sparber F, Tripp CH, Hermann M, Romani N, Stoitzner P. Langerhans cells and dermal dendritic cells capture protein antigens in the skin: Possible targets for vaccination through the skin. Immunobiology, 2010;215:770–9
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater Res, 1988;22:837–58
   PubMed Web of Science ®Google Scholar
• Thiele L, Merkle HP, Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm Res, 2003;20:221–8
   PubMed Web of Science ®Google Scholar
• Uddin AN, Bejugam NK, Gayakwad SG, Akther P, D'Souza MJ. Oral delivery of gastro-resistant microencapsulated typhoid vaccine. J Drug Target, 2009;17:553–60
   PubMed Web of Science ®Google Scholar
• Vieweg J. Immunotherapy for advanced prostate cancer. Rev Urol, 2007;9(Suppl 1):S29–38
   PubMedGoogle Scholar
• Xiang SD, Scalzo-Inguanti K, Minigo G, Park A, Hardy CL, Plebanski M. Promising particle-based vaccines in cancer therapy. Expert Rev Vaccin, 2008;7:1103–19
   PubMed Web of Science ®Google Scholar
• Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: Prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res, 2001;61:5857–60
   Google Scholar
• Yeboah KG, D'Souza MJ. Evaluation of albumin microspheres as oral delivery system for Mycobacterium tuberculosis vaccines. J Microencapsul, 2009;26:166–79
   PubMed Web of Science ®Google Scholar